Signalling pathways as targets for anticancer drug development.
Signalling pathways as targets for anticancer drug development.
复制标题
信号通路作为抗癌药物开发的靶点。
DOI：
10.1016/0163-7258(94)90005-1
复制
发表时间：
1994
影响因子：
13.5
通讯作者：
Powis,G
中科院分区：
文献类型：
--
作者：
Powis,G
细胞内信号通路介导癌基因对细胞生长和转化的影响，为抗癌药物的开发提供了新的靶点。通过这种方法，可能足以针对致癌基因激活的信号通路的一个组成部分，而不是致癌基因产物本身。在这篇综述中，考虑了一些抗增殖药物抑制信号靶点的能力。有一些抗癌药物已经在临床试验中，可能通过抑制信号靶点起作用，以及在临床前开发的药物。讨论了开发这类新型抗癌药物可能遇到的一些问题。
Intracellular signalling pathways mediating the effects of oncogenes on cell growth and transformation offer novel targets for the development of anticancer drugs. With this approach, it may be sufficient to target a component of the signalling pathway activated by the oncogene rather than the oncogene product itself. In this review, teh abilities of some antiproliferative drugs to inhibit signalling targets are considered. There are some anticancer drugs already in clinical trial that may act by inhibiting signalling targets, as well as drugs in preclinical development. Some problems that may be encountered in developing this new class of anticancer drugs are discussed.